Literature DB >> 11194941

Prion protein expression in senile plaques in Alzheimer's disease.

I Ferrer1, R Blanco, M Carmona, B Puig, R Ribera, M J Rey, T Ribalta.   

Abstract

Prion protein (PrPC) is a glycolipid-anchored cell membrane sialoglycoprotein that localises in presynaptic membranes. Since synapses are vulnerable to Alzheimer's disease (AD), the present study examines PrPC expression in senile plaques, one of the major structural abnormalities in AD, by single- and double-labelling immunohistochemistry. Punctate PrPC immunoreactivity is found in diffuse plaques, whereas isolated large coarse PrPC-positive granules reminiscent of dystrophic neurites are observed in neuritic plaques. Finally, PrPC deposition also occurs as dense filamentous and amorphous precipitates in amyloid cores of senile plaques, but not in the walls of blood vessels with amyloid angiopathy. In contrast to PrPC, betaA4-amyloid immunoreactivity is preserved and even enhanced following incubation of the tissue sections with proteinase K prior to immunohistochemistry, thus indicating no PrPC and betaA4-amyloid cross-reactivity in dense amyloid cores of senile plaques. Punctate PrPC deposition in diffuse plaques is similar to that of synaptophysin, a synaptic vesicle-associated protein, as already reported in other studies. Immunoprecipitation, electrophoresis and Western blot studies have shown that synaptophysin, amyloid precursor protein (APP) and betaA4 do not co-precipitate with PrP. These results suggest that synaptophysin, APP and betaA4 are likely not bound to PrP. PrPC accumulation in betaA4-amyloid dense cores may be the consequence of the release of PrP into the extracellular space. Whether PrPC accumulation in the extracellular space is the result of impaired endocytosis and subsequent hydrolysis in the endosomal compartment, in contrast to normal degradation of PrPC, resulting from or occurring in parallel to abnormal APP degradation, deserves further study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11194941     DOI: 10.1007/s004010000271

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  39 in total

1.  Comment on "The codon 129 polymorphism of the prion protein gene influences earlier cognitive performance in Down syndrome subjects"--by Del Bo et al. in J Neurol (2003) 250:688-692.

Authors:  Alisdair McNeill
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

2.  Prion protein gene M129 allele is a risk factor for Alzheimer's disease.

Authors:  M Gacia; K Safranow; M Styczyńska; K Jakubowska; B Pepłońska; M Chodakowska-Zebrowska; I Przekop; A Słowik; E Golańska; K Hułas-Bigoszewska; D Chlubek; D Religa; C Zekanowski; M Barcikowska
Journal:  J Neural Transm (Vienna)       Date:  2006-08-08       Impact factor: 3.575

3.  Interaction between prion protein and interleukin-1A genes increases early-onset Alzheimer's disease risk.

Authors:  Onofre Combarros; Javier Llorca; Pascual Sánchez-Juan; Ignacio Mateo; Jon Infante; Eloy Rodríguez; Coro Sánchez-Quintana; José Berciano
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

4.  Alzheimer's amyloid-β oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway.

Authors:  Rong-Jie Chen; Wei-Wei Chang; Yu-Chun Lin; Pei-Lin Cheng; Yun-Ru Chen
Journal:  ACS Chem Neurosci       Date:  2013-07-18       Impact factor: 4.418

Review 5.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

Review 6.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

7.  S100A6 amyloid fibril formation is calcium-modulated and enhances superoxide dismutase-1 (SOD1) aggregation.

Authors:  Hugo M Botelho; Sónia S Leal; Isabel Cardoso; Kiran Yanamandra; Ludmilla A Morozova-Roche; Günter Fritz; Cláudio M Gomes
Journal:  J Biol Chem       Date:  2012-10-17       Impact factor: 5.157

8.  Role of PrP(C) Expression in Tau Protein Levels and Phosphorylation in Alzheimer's Disease Evolution.

Authors:  C Vergara; L Ordóñez-Gutiérrez; F Wandosell; I Ferrer; J A del Río; R Gavín
Journal:  Mol Neurobiol       Date:  2014-06-26       Impact factor: 5.590

9.  The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers.

Authors:  Nadine D Younan; Claire J Sarell; Paul Davies; David R Brown; John H Viles
Journal:  FASEB J       Date:  2013-01-18       Impact factor: 5.191

Review 10.  Cross currents in protein misfolding disorders: interactions and therapy.

Authors:  Rodrigo Morales; Kristi M Green; Claudio Soto
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-11       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.